As part of a two-day state visit to Turkey, representatives of the Single Distributor visited the biotechnological production site of the global company Nobel Ilac plant and discussed issues of joint implementation of projects with the head of the company, Hasan Ulusa. The production site of Nobel Ilac is located in the special technological development zone of the Republic of Turkey - MarmaraTeknokent.
Marmara Teknokent is one of the first innovation technology parks in Turkey, where research and development, supported by the creation of a strong and effective entrepreneurial capacity, is transformed into high-tech products, methods or services with high added value, mass production is carried out, products are commercialized for export and become an international brand, able to compete in the international market. Through the strategic work of Marmara Teknokent with global partnerships, R&D oriented projects are being created.
During the visit, representatives of the Single Distributor got acquainted with the activities of R&D centers and the latest developments of the company. And a meeting was held with the research unit and the experience of the Republic of Turkey in supporting the DGP in pharmaceuticals was discussed.
In the Message to the people, the Head of State of the Republic of Kazakhstan noted the importance of cooperation with global pharmaceutical corporations, attracting investors, ensuring the transfer of technologies and the latest developments.
As part of the activities carried out to support the development of domestic production of pharmaceutical products, the Single Distributor takes the initiative to provide a platform for major drug brands to enter the country from packaging to the full production cycle.
Thus, in order to implement measures to develop the pharmaceutical industry in Kazakhstan, the Single Distributor holds meetings with major players in the global pharmaceutical industry, during which their long-term plans for presence in the Kazakh pharmaceutical market and investment in the industry are discussed.
Nobel Ilac is active in the field of biotechnology and biosimilar products through co-development and licensing. In 2005, Nobel İlaç, the first pharmaceutical company in Turkey, conducted a clinical trial of Interferon Alpha Phase II, continuing its biotechnology research started with its own capital and subsequent government support. In 2015, among 28 projects and 21 companies, Nobel İlaç was selected as the only company to receive the US$10 million KAMAG 1007 project, and the first national biosimilar project (BIOSIM-1) was initiated under this project. With the joint support of the TÜBİTAK Research Foundation and Bilkent University, the bi-mAb recombinant project was launched in 2016, which is the first project to develop a biotechnological original molecule. IFC (International Finance Corporation) has invested US$25 million in Nobel İlaç's biotech pharmaceutical manufacturing facility.
Nobel Ilaç also supports high-value-added drugs on the local and international markets and covers the foreign trade deficit in the pharmaceutical sector in Turkey. The company, focusing on the development of biotechnologies of the original molecule, in addition to biosimilar investments, has set a goal for itself to increase the international competitiveness of both the company and Turkey.
During the state visit to Turkey, the Minister of Health of the Republic of Kazakhstan signed a bilateral cooperation Agreement on the construction of a second pharmaceutical plant in Almaty for the production of pharmaceuticals with the head of the pharmaceutical company Nobel Ilac, and also signed a cooperation Agreement on the construction of a pharmaceutical production plant in Almaty with the head of Atabay.
It should be noted that Nobel Ilac plans to invest an additional $55 million in the modernization and expansion of existing production, as well as the construction of a second pharmaceutical plant in Almaty, where the production of drugs in the form of sachets and high-tech biosimilars will be launched. Currently, a feasibility study and design estimates for the project are being developed. This procedure is planned to be completed by the end of the first half of 2022 and to begin the phased implementation of the project with full completion in December 2025.
As part of the development of Kazakh-Turkish cooperation in Kazakhstan, the possibility of creating an R&D center managed by Nobel Ilac is being discussed. The purpose of this R&D center will be the development of original molecules, biosimilars, marketing research, as well as the formation of a pool of narrow specialists in close cooperation with domestic and Turkish universities for the needs of the pharmaceutical industry in Kazakhstan.
It should be noted that this enterprise will allow developing the domestic production of original medicines and medical devices, increasing the export potential of domestic pharmaceutical products, as well as increasing scientific and human resources.
It should be recalled that this year marks exactly 20 years since the founding of the joint Kazakh plant of Nobel AFF JSC for the production of pharmaceutical products.
At the end of the meetings, the parties mutually expressed their opinion on the importance of developing Kazakh-Turkish cooperation in the healthcare sector, including the pharmaceutical industry. Today, the two fraternal countries are jointly working on dozens of investment projects worth billions of dollars, and there is no doubt that cooperation between the countries will only expand.
Reference:
ATABAY Pharmaceuticals&Fine Chemicals is a family–owned Turkish pharmaceutical company founded in 1939 in Istanbul. The main direction of the company is the production of generic (cheaper analogue of original medicines) medicines and active pharmaceutical ingredients (API). ATABAY produces more than 100 types of pharmaceuticals, agricultural and veterinary chemicals, including antibiotics, antihistamines, anti-cancer, anti-tuberculosis and other medicines according to the international GMP (good manufacturing practices) standard. ATABAY exports its products to the USA, Europe, Asia, the Middle East and North Africa. The company has two production sites in the cities of Gebze (ATABAY Gebze Plant – 10,000 sq.m.) and Ajibadem (ATABAY Acıbadem Plant – 50,000 sq.m.).
Nobel Pharmaceuticals, a global Nobel company with more than half a century of experience, was founded in 1964 with one hundred percent internal capital. Today, Nobel has five production complexes, three of which are located in Turkey, one in Kazakhstan and one in Uzbekistan. The company conducts advertising and trade events of its own organization in 20 countries around the world. The Nobel company, which employs about 3,000 people, exports its high-quality products manufactured in accordance with international standards to about 50 countries around the world. It operates through its own companies opened in such countries as Germany, Albania, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Georgia, Switzerland, Montenegro, Kazakhstan, Kyrgyzstan, Kosovo, Macedonia, Mongolia, Moldova, Uzbekistan, Russia, Serbia, Turkmenistan and Ukraine.
.png)
.png)
.jpeg)